Abstract
Little progress has been made in the pharmacological management of patients with hepatic encephalopathy, partly because it is difficult to perform clinical trials in this group of patients. A new clinical trial now suggests that polyethylene glycol is more effective than the current standard first-line therapy in these patients.
MeSH terms
-
Gastrointestinal Agents / therapeutic use
-
Hepatic Encephalopathy / drug therapy*
-
Hepatic Encephalopathy / physiopathology
-
Humans
-
Intestines / drug effects
-
Intestines / physiopathology
-
Lactulose / pharmacology
-
Lactulose / therapeutic use
-
Polyethylene Glycols / pharmacology
-
Polyethylene Glycols / therapeutic use*
-
Rifamycins / pharmacology
-
Rifamycins / therapeutic use
-
Rifaximin
-
Treatment Outcome
Substances
-
Gastrointestinal Agents
-
Rifamycins
-
Polyethylene Glycols
-
Lactulose
-
Rifaximin